NCT03935932View on ClinicalTrials.gov

Study of Humidified Air to Improve Mucociliary Clearance (MCC) in COPD

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 15, 2019

Primary Completion Date

February 15, 2021

Study Completion Date

February 15, 2021

Conditions
COPD
Interventions
DEVICE

nasal delivery of heated and humidified air

Subjects will receive nasal delivery of heated and humidified air (plus oxygen if needed) at 30 liters/minute from the Fisher and Paykel myAirvo2 heater/humidifier using an Optiflow nasal cannula.

Trial Locations (1)

15213

University of Pittsburgh Medical Center, Pittsburgh

All Listed Sponsors
collaborator

Fisher and Paykel Healthcare

INDUSTRY

lead

Frank C Sciurba

OTHER

NCT03935932 - Study of Humidified Air to Improve Mucociliary Clearance (MCC) in COPD | Biotech Hunter | Biotech Hunter